GlassScriptPhysician profile
Michael J Schierman
NPI 1427128131
$9,260.26
in general payments reported to CMS, 2019-2025
40 companies · $2,006 in 2025
The $2,006 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,212 · 2020: $996 · 2021: $1,579 · 2022: $957 · 2023: $631 · 2024: $1,879 · 2025: $2,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,516.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,515.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,110.90 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $971.57 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $865.98 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $841.14 | 2019-2025 | Evenity, Prolia |
| Pfizer INC. | $803.33 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $663.86 | 2019-2025 | Jardiance |
| Abbvie INC. | $544.21 | 2020-2025 | Ubrelvy |
| Biohaven Pharmaceuticals, INC. | $396.35 | 2021 | |
| Allergan, INC. | $368.03 | 2019-2020 | |
| Exact Sciences Corporation | $344.28 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $310.16 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $262.76 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $257.35 | 2019-2025 | Xifaxan, Trulance |
| Teva Pharmaceuticals USA, INC. | $180.46 | 2019-2020 | |
| Bausch Health US, LLC | $157.58 | 2020-2025 | Aplenzin, Wellbutrin |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Schierman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.